GLTO Quote, Financials, Valuation and Earnings

Humana, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of -2.39%. Galecto, Inc.'s return on equity of -123.72% beat Humana, Inc.'s return on equity of 6.77%.

Galecto, Inc. has a consensus price target of $44.33, signalling upside risk potential of 52.24%. On the other hand Humana, Inc. has an analysts' consensus of $231.57 which suggests that it could grow by 25.78%. Given that Galecto, Inc. has higher upside potential than Humana, Inc., analysts believe Galecto, Inc. is more attractive than Humana, Inc..

Galecto, Inc. has a beta of 1.422, which suggesting that the stock is 42.247% more volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.287%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana, Inc. offers a yield of 1.92% to investors and pays a quarterly dividend of $0.89 per share. Galecto, Inc. pays -- of its earnings as a dividend. Humana, Inc. pays out 35.98% of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Galecto, Inc. quarterly revenues are --, which are smaller than Humana, Inc. quarterly revenues of $32.5B. Galecto, Inc.'s net income of -$3.1M is higher than Humana, Inc.'s net income of -$776M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Humana, Inc.'s PE ratio is 18.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 0.17x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Natera, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of -14.78%. Galecto, Inc.'s return on equity of -123.72% beat Natera, Inc.'s return on equity of -26.6%.

Galecto, Inc. has a consensus price target of $44.33, signalling upside risk potential of 52.24%. On the other hand Natera, Inc. has an analysts' consensus of $257.20 which suggests that it could grow by 24.72%. Given that Galecto, Inc. has higher upside potential than Natera, Inc., analysts believe Galecto, Inc. is more attractive than Natera, Inc..

Galecto, Inc. has a beta of 1.422, which suggesting that the stock is 42.247% more volatile than S&P 500. In comparison Natera, Inc. has a beta of 1.636, suggesting its more volatile than the S&P 500 by 63.611%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Natera, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Natera, Inc. quarterly revenues of $592.2M. Galecto, Inc.'s net income of -$3.1M is higher than Natera, Inc.'s net income of -$87.5M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Natera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 13.15x for Natera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palvella Therapeutics, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of --. Galecto, Inc.'s return on equity of -123.72% beat Palvella Therapeutics, Inc.'s return on equity of -101.06%.

Galecto, Inc. has a consensus price target of $44.33, signalling upside risk potential of 52.24%. On the other hand Palvella Therapeutics, Inc. has an analysts' consensus of $187.87 which suggests that it could grow by 130.4%. Given that Palvella Therapeutics, Inc. has higher upside potential than Galecto, Inc., analysts believe Palvella Therapeutics, Inc. is more attractive than Galecto, Inc..

Galecto, Inc. has a beta of 1.422, which suggesting that the stock is 42.247% more volatile than S&P 500. In comparison Palvella Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palvella Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Palvella Therapeutics, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Palvella Therapeutics, Inc. quarterly revenues of --. Galecto, Inc.'s net income of -$3.1M is higher than Palvella Therapeutics, Inc.'s net income of -$11.3M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Palvella Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus -- for Palvella Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of 21.74%. Galecto, Inc.'s return on equity of -123.72% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Galecto, Inc. has a consensus price target of $44.33, signalling upside risk potential of 52.24%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 8.08%. Given that Galecto, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Galecto, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Galecto, Inc. has a beta of 1.422, which suggesting that the stock is 42.247% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. Galecto, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Galecto, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Galecto, Inc.'s net income of -$3.1M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 6.08x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.